ויאגרה 50 מג ישראל - עברית - Ministry of Health

ויאגרה 50 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ויאגרה 100 מג ישראל - עברית - Ministry of Health

ויאגרה 100 מג

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

בינוקריט 8000 יחבל  0.8 מל ישראל - עברית - Ministry of Health

בינוקריט 8000 יחבל 0.8 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin

סודיום כלוריד % 0.9 לעירוי לתוך הוריד BP ישראל - עברית - Ministry of Health

סודיום כלוריד % 0.9 לעירוי לתוך הוריד bp

teva medical marketing ltd. - sodium chloride - תמיסה לאינפוזיה - sodium chloride 0.9 %w/v - sodium chloride

אסריל 25 ישראל - עברית - Ministry of Health

אסריל 25

dexcel ltd, israel - captopril - טבליה - captopril 25 mg - captopril - captopril - hypertension, congestive heart failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl. left ventricular dysfunction after myocardial infarction. captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40 % and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

אסריל 50 ישראל - עברית - Ministry of Health

אסריל 50

dexcel ltd, israel - captopril - טבליה - captopril 50 mg - captopril - captopril - hypertension, congestive heart failure, insulin dependent diabetic nephropathy in hypertensive and non hypertensive patients in cases where the serum creatinine level < 2.5 mg/dl. left ventricular dysfunction after myocardial infarction. captopril is indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction < or equals to 40 % and to reduce the incidence of overt heart failure and subsequent hospitalization for congestive heart failure in these patients.

גאמאגארד S/D אימונוגלובולין תוך ורידי 2.5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 2.5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 10 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 10 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

ויגאם ליקוויד ישראל - עברית - Ministry of Health

ויגאם ליקוויד

kamada ltd - immunoglobulin normal human 5 %w/v - liquid - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiency severe combined immunodeficiency wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenic purpura (itp) in children or adults at high risk of bleeding spontaneously or prior to surgery to correct the platelet count guillain barre syndrome and kawasaki disease. allogeneic bone marrow transplantation.